1 |
Rhee SK, Kang YK, Park WJ, Chung YG, Lee HJ. Malignant melanoma. J Korean Bone & Joint Tumor Soc. 2001;7:12-9.
|
2 |
Nahabedian MY. Malignant melanoma. Clin Plast Surg. 2005; 32:249-59.
DOI
ScienceOn
|
3 |
Rigel DS, Carucci JA. Malignant melanoma: prevention, early detection, and treatment in the 21st century. CA Cancer J Clin. 2000;50:215-36.
DOI
ScienceOn
|
4 |
Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-48.
DOI
|
5 |
Park JH, Lee HS, Ham DH, Kim JR. An analysis of the prognostic factors of malignant melanoma. J Korean Bone & Joint Tumor Soc. 2009;15:122-9.
|
6 |
Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, Chanmugam A. Cutaneous malignant melanoma. Mayo Clin Proc. 2006;81:500-7.
DOI
ScienceOn
|
7 |
Clark WH. A classification of malignant melanoma in man correlated with histiogenesis and biologic behavior. Adv Biol Skin. 1976;8:621-47.
|
8 |
Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1790;172:902-8.
|
9 |
Verma S, McCready D, Bak K, Charette M, Iscoe N. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer. 2006;106:1431-42.
DOI
ScienceOn
|
10 |
Sekulic A, Haluska P, Miller AJ, et al. Malignant melanoma in the 21st century: the emerging mole cular landscape. Mayo Clin Proc. 2008;83:825-46.
DOI
ScienceOn
|
11 |
Su WP. Malignant melanoma: basic approach to clinicopathologic correlation. Mayo Clin Proc. 1997;72:267-72.
DOI
|